Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate PK and Safety in Advanced Cancer with Hepatic Impairment
NCT07036133Phase 1Recruiting
- Sponsor
- Acrotech Biopharma Inc
- Start
- Dec 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pralatrexate in solid tumor (advanced stage) and hematologic malignancy, sponsored by Acrotech Biopharma Inc. Primary endpoint: Pharmacokinetic profile at 1 week. Started Dec 2022; status: recruiting.
02
Drugs
pralatrexate
03
Conditions
solid tumor (advanced stage)hematologic malignancy
Beyond the preview
Go deeper on NCT07036133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036133.